Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-06-16 5:21 pm Unchanged |
2023-06-15 | 13D | Cazoo Group Ltd CZOO |
Farallon Capital Partners, L.P. | 10,000 2.600% |
0 (Unchanged) |
Filing History |
| 2023-06-02 4:59 pm Purchase |
2023-05-31 | 13D | Exelixis, Inc. EXEL |
Farallon Capital Partners, L.P. | 25,860,000 7.900% |
2,394,000 (+10.20%) |
Filing History |
| 2023-05-16 5:25 pm Unchanged |
2023-05-12 | 13D | Cazoo Group Ltd CZOO |
Farallon Capital Partners, L.P. | 10,000 2.600% |
0 (Unchanged) |
Filing History |
| 2023-04-27 5:28 pm Unchanged |
2023-04-25 | 13D | Cazoo Group Ltd CZOO |
Farallon Capital Partners, L.P. | 10,000 2.600% |
0 (Unchanged) |
Filing History |
| 2023-04-06 8:54 pm Unchanged |
2023-04-05 | 13D | Exelixis, Inc. EXEL |
Farallon Capital Partners, L.P. | 23,466,000 7.200% |
0 (Unchanged) |
Filing History |
| 2023-04-06 4:58 pm Purchase |
2023-03-29 | 13G | Forest Road Acquisition Corp. II FRXB |
Farallon Capital Partners, L.P. | 400,000 8.900% |
400,000 (New Position) |
Filing History |
| 2023-03-27 4:33 pm Unchanged |
2023-03-23 | 13D | Exelixis, Inc. EXEL |
Farallon Capital Partners, L.P. | 23,466,000 7.200% |
0 (Unchanged) |
Filing History |
| 2023-03-24 1:34 pm Purchase |
2023-03-17 | 13D | Cazoo Group Ltd CZOO |
Farallon Capital Partners, L.P. | 10,000 2.500% |
10,000 (New Position) |
Filing History |
| 2023-03-20 4:39 pm Purchase |
2023-03-09 | 13D | Exelixis, Inc. EXEL |
Farallon Capital Partners, L.P. | 23,466,000 7.200% |
23,466,000 (New Position) |
Filing History |
| 2023-02-17 3:20 pm Purchase |
2023-02-08 | 13G | AVROBIO, Inc. AVRO |
Farallon Capital Partners, L.P. | 259,667 7.100% |
259,667 (New Position) |
Filing History |
| 2023-02-14 08:27 am Sale |
2022-12-31 | 13G | Beam Therapeutics Inc. BEAM |
Farallon Capital Partners, L.P. | 3,399,921 4.800% |
-151,850 (-4.28%) |
Filing History |
| 2023-02-09 4:55 pm Unchanged |
2022-12-31 | 13G | Shelter Acquisition Corporation I SHQA |
Farallon Capital Partners, L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2023-02-09 4:55 pm Purchase |
2022-12-31 | 13G | Swiftmerge Acquisition Corp. IVCP |
Farallon Capital Partners, L.P. | 2,205,000 9.700% |
2,205,000 (New Position) |
Filing History |
| 2023-02-09 4:54 pm Purchase |
2022-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
Farallon Capital Partners, L.P. | 5,055,102 9.990% |
5,055,102 (New Position) |
Filing History |
| 2023-02-07 5:10 pm Sale |
2022-12-31 | 13G | Better Therapeutics, Inc. BTTX |
Farallon Capital Partners, L.P. | 813,556 3.400% |
-536,444 (-39.74%) |
Filing History |
| 2023-02-07 5:09 pm Sale |
2022-12-31 | 13G | Clarivate Plc CLVT |
Farallon Capital Partners, L.P. | 15,177,433 2.300% |
-20,148,467 (-57.04%) |
Filing History |
| 2023-02-07 5:09 pm Purchase |
2022-12-31 | 13G | AMYRIS INC AMRSQ |
Farallon Capital Partners, L.P. | 1,000,000 0.300% |
1,000,000 (New Position) |
Filing History |
| 2023-02-06 4:20 pm Unchanged |
2022-12-31 | 13G | SEP Acquisition Corp. SEPA |
Farallon Capital Partners, L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2023-02-06 09:06 am Purchase |
2022-12-31 | 13G | Enanta Pharmaceuticals, Inc. ENTA |
Farallon Capital Partners, L.P. | 1,550,000 7.500% |
1,550,000 (New Position) |
Filing History |
| 2023-02-03 5:16 pm Purchase |
2022-12-31 | 13G | Savara Inc. SVRA |
Farallon Capital Partners, L.P. | 11,532,622 9.990% |
11,532,622 (New Position) |
Filing History |